Biostrol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biostrol

Quick Facts

Property Description
Active ingredient Anastrozole
Form Oral Tablet
Pharmacological class Non-Steroidal Aromatase Inhibitor (AI)
Common purpose Estrogen biosynthesis suppression
Origin Synthetic (Triazole compound)

What Type of Drug is Biostrol (Anastrozole)?

Biostrol is a synthetic, prescription-only pharmaceutical agent containing Anastrozole as its active ingredient. It is formally classified as a non-steroidal aromatase inhibitor (AI), a pharmacological class that is clinically recognized for its specific mechanism in hormone manipulation. The compound itself is structurally identified as a triazole derivative, which confirms its position as a potent endocrine agent.

The drug is distinguished from older therapies by its high specificity. As a third-generation inhibitor, Anastrozole is recognized in pharmacological studies for achieving substantial, near-maximal inhibition of the aromatase enzyme. Biostrol maintains this compound's intrinsic design, delivered via a simple oral tablet for consistent systemic action.

How Does Biostrol Affect the Body's Chemistry?

The general therapeutic purpose of Biostrol is to achieve powerful estrogen biosynthesis suppression by blocking a single, crucial metabolic step. It acts as a highly selective enzyme inhibitor that directly targets the aromatase enzyme. This enzyme is responsible for the peripheral tissue conversion of androgens into estrogen.

By competitively blocking this enzyme, the Anastrozole component effectively prevents the production of estrogen throughout the body. The resulting creation of a low-estrogen environment is the goal of the treatment. This action establishes Biostrol as a specific and effective agent for managing conditions sensitive to the presence of circulating estrogen.

Regulatory References

  1. MedlinePlus: Anastrozole Drug Information

What side effects are possible with Biostrol?

Possible Side Effects and Safety Information

The safety profile of Biostrol (Anastrozole) is officially documented by government regulatory authorities based on findings from clinical studies in the target population. Adverse reactions are classified by frequency and grouped according to the physiological system affected. The purpose of this information is strictly to communicate the documented safety characteristics of the medicine, as detailed in official regulatory texts.


Classification of Adverse Reactions

Adverse reactions are ranked by occurrence frequency as established in the product's official prescribing information. The most frequently reported effects (classified as Very Common, affecting 1 in 10 people or more) typically involve the musculoskeletal system, presenting as arthralgia (joint pain), and general systemic effects such as hot flushes and asthenia (lack of energy).

Reactions classified as Common (affecting 1 in 100 to 1 in 10 people) span several organ systems. These include disturbances of the nervous system, such as headache and somnolence (drowsiness), gastrointestinal tract effects like nausea and vomiting, and dermatological manifestations such as rash and alopecia (hair thinning).

Serious Adverse Reactions and Systemic Concerns

Regulatory safety data documents less frequent but clinically important risks. These include rare and very rare systemic reactions such as Erythema multiforme and Stevens-Johnson syndrome, as well as reports of anaphylactoid reactions. The safety profile also includes documentation of thromboembolic events and ischemic cardiac events.

Safety Considerations for Specific Populations

Biostrol is formally contraindicated in women who are pre-menopausal, pregnant, or breastfeeding. Caution is advised for individuals with existing severe hepatic or renal impairment. Furthermore, the increased risk of bone fracture and osteoporosis is recognized as a long-term consequence associated with the therapeutic reduction of circulating estrogen.

Overdose and Emergency Response

Overdose Presentations and Risk Profile

The official regulatory documentation for Biostrol (Anastrozole) overdose indicates a low intrinsic acute toxicity profile. Clinical studies have shown that the compound was well tolerated at single high doses, and there is no established dose that is known to be life-threatening. Regulatory labeling notes the absence of a specific, distinct symptom profile associated with massive overdose, placing the emphasis on immediate action rather than specific manifestations.

Emergency Action and Supportive Management

Immediate medical attention must be sought for any suspected overdose event. This requirement is mandated regardless of the presence or severity of immediate symptoms. Management must be entirely symptomatic and supportive, as no specific antidote is known for Anastrozole. Procedural steps noted in official documents include the potential to induce vomiting if the patient is alert and the suggestion that dialysis may be helpful, given the drug is not highly protein bound.

Required Monitoring

  • Frequent monitoring of vital signs is required.
  • Close observation of the patient by a medical professional is mandated.
  • The management strategy must consider the possibility that multiple pharmacological agents may have been taken in the overdose context.

Therapeutic Uses of Biostrol

What Biostrol Treats: Main Uses and Benefits

Biostrol (Anastrozole) is a medication generally used in conditions presenting with acute episodes of hormone-sensitive malignant disease in postmenopausal women. It is applied across domains where additional symptomatic support is needed due to heightened physiological activity. The medication is commonly used in situations involving certain distressing symptoms related to the potential return of cancer, advanced disease progression, or high-risk status.


Therapeutic Contexts and Benefits

This medication is applied across domains where additional symptomatic support is needed, such as following primary treatments or when supporting the management of locally advanced disease. It supports patients during episodes of heightened discomfort by addressing symptom clusters that may become intense or disruptive. It helps manage conditions where symptoms may intensify temporarily and contributes to easing the overall symptom load over time.

“It plays a role in managing the potential for the condition to return, which supports general well-being during symptomatic phases.”

Quick Fact: Relief for Cancer-Related Risk
Common Use Context: Supportive management following primary cancer treatment or for primary risk mitigation.
Main Benefit: Assists with maintaining functional stability and managing the potential for disease recurrence or progression.
Targeted Conditions: Conditions involving episodic or fluctuating manifestations of malignant disease.

Regulatory References

  1. NIH MedlinePlus overview of Anastrozole

Eligibility and Restrictions for Use

The eligibility for Biostrol (Anastrozole) is strictly defined by regulatory documents, centering on a patient's hormonal status and specific exclusionary criteria.

Eligibility Status Defined Population
Approved Use Postmenopausal women are the primary eligible population. Use is established and standard for older adults (geriatric patients) without requiring age-specific dose adjustments.
Absolute Contraindications Premenopausal women must not use this medicine; menopausal status must be confirmed. Use is prohibited during pregnancy and lactation. It is also contraindicated for patients with known hypersensitivity to anastrozole or any excipients, and those with specific hereditary metabolic disorders like galactose intolerance.
Not Recommended/Caution Use is not recommended for children and adolescents, as safety and efficacy have not been established in this group. Administration requires caution in patients with severe renal impairment (GFR <30 ml/min) or moderate-to-severe hepatic impairment. Caution is also advised for patients with pre-existing ischemic heart disease. Additionally, patients at risk of bone loss must undergo mandatory bone mineral density assessment and monitoring.

The regulatory profile imposes absolute prohibitions based on reproductive status and specific comorbidities, ensuring the drug is only administered within its officially studied and approved patient populations.

What should I know about interactions with other medicines?

The official regulatory profile for Biostrol (Anastrozole) establishes several critical interaction constraints, categorized primarily as contraindicated combinations and pharmacokinetic outcomes.

Contraindicated Combinations Co-administration with Estrogen-containing therapies is formally contraindicated. This restriction is based on pharmacodynamic antagonism, as estrogenic agents (such as estradiol or conjugated estrogens) directly oppose and diminish the intended effect of Biostrol. Similarly, the combination with Tamoxifen is contraindicated. This is due to a pharmacokinetic interaction where Tamoxifen reduces the plasma concentration of Anastrozole by 27%, and the combination offers no additional clinical benefit.

Pharmacokinetic and Metabolic Status The drug’s interaction with key metabolic enzymes is considered minor. While Anastrozole demonstrates in vitro inhibition of certain cytochrome P450 enzymes (CYP1A2, 2C8/9, and 3A4), regulatory findings conclude that co-administration with other medicines is unlikely to result in clinically significant inhibition of CYP-mediated metabolism. Studies with Warfarin found no alteration in its anticoagulant activity or pharmacokinetic profile, establishing this as a clinically insignificant interaction. Furthermore, food does not affect the overall extent of absorption, meaning the drug can be taken independently of meals.

Population Notes In patients with severe hepatic or renal impairment, Anastrozole clearance is documented to be reduced by 30% to 50%. However, official labeling states that this pharmacokinetic change does not necessitate dosage adjustment for these specific populations.

Mechanism of Action

Biostrol's mechanism is highly specific, intervening in a single hormonal biosynthesis pathway to induce systemic physiological change. Its core action involves the active ingredient, Anastrozole, a non-steroidal competitive inhibitor that targets the Aromatase enzyme (CYP19A1). This enzyme, found primarily in peripheral tissues, converts androgens into estrogens. By reversibly binding to the enzyme’s active site, Biostrol blocks this final synthesis step, initiating a cascade that leads to a significant and rapid reduction in circulating Estradiol and Estrone.

The molecular blockade establishes a selective low-estrogen environment. This systemic reduction constitutes the primary functional result, altering downstream cellular signaling dependent upon estrogenic stimulation. Importantly, this mechanism does not inhibit other essential hormone synthesis pathways, such as those governing cortisol or aldosterone, which defines its selectivity. However, the mechanism is fundamentally weak in the presence of high, gonadotropin-driven estrogen production from active ovaries (premenopausal state), where peripheral inhibition is insufficient to reduce systemic estrogen concentration to the level produced by peripheral aromatization alone, defining a physiological limitation tied to the hormone source.

Dosage and Administration Information

How Biostrol is Used: Official Administration Guidelines

Biostrol (Anastrozole) is administered according to a specific, standardized protocol. The instructions detailed below define the route, dosage, frequency, and conditions for use.


Dosing and Route of Administration

The medication is provided as a 1 mg film-coated tablet and is taken via the oral route. This 1 mg dose is the standardized regimen for all approved contexts of use in postmenopausal women. The tablet must be taken once daily (qDay), consistently, as directed.

Administration Detail Official Guideline
Standard Daily Dose 1 mg
Frequency Once Daily
Intake Condition Can be taken with or without food.
Administration Restriction Co-administration with tamoxifen or estrogen-containing therapies should be avoided.

Duration and Specific Use Contexts

Biostrol is not a short-term treatment; the duration of use is defined based on the treatment goal:

  • Adjuvant Treatment: The recommended course duration is typically five years.
  • Advanced Disease: Treatment is continued until tumor progression.

Population-Specific Use

Specific guidance exists for certain patient groups, though the standard 1 mg dose generally remains fixed:

  • Elderly Patients: No dosage adjustment is necessary.
  • Renal/Hepatic Impairment: No dose change is recommended for patients with mild-to-moderate renal or hepatic impairment. Caution is advised in cases of severe impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biostrol

Biostrol (Anastrozole) has been the subject of extensive international research, primarily through large-scale, long-running clinical trials. This evidence contributes to describing what has been observed so far in specific patient groups, contributing to the broader evidence landscape but research does not determine whether an individual will respond similarly.


Evidence for Adjuvant Treatment of Early-Stage Hormone Receptor-Positive Malignant Disease

Researchers studied Biostrol in large, multi-year Randomized Controlled Trials (RCTs) involving thousands of postmenopausal women who had completed definitive surgery. These studies compared outcomes, including the time until the malignant disease reappeared (Time to Recurrence) and disease-free survival, over a five-year treatment period and beyond. Studies also monitored the incidence of a new primary cancer appearing in the opposite breast. Findings described patterns in these high-level clinical outcomes, with follow-up durations extending for over ten years in some cohorts. Study results reflect the specific conditions under which they were conducted and apply only to the populations studied in these large trials.

Evidence for First-line Treatment of Advanced Hormone Receptor-Positive Malignant Disease

Phase III trials explored Biostrol as an initial treatment in postmenopausal women with locally advanced or metastatic disease, often comparing it with other endocrine therapies. Researchers monitored measurements such as the Objective Response Rate (ORR), reflecting tumor shrinkage, and the Time to Progression (TTP), the interval before the disease starts growing again. Trial reports described patterns in the progression-free interval for patients receiving the study medication. Limited information is available concerning outcomes in patients presenting with extensive organ involvement (such as severe liver metastases), as these patients were often not included in the primary trials.

Evidence for Extended Adjuvant Treatment Following Initial Therapy

Research examined Biostrol in studies where postmenopausal women who had completed five years of initial endocrine therapy were assigned to receive either Biostrol for an additional period or to enter an observation period. These studies were designed to evaluate the effect of this extended course of action on measured outcomes. The certainty remains low regarding the absolute optimal duration of extended adjuvant treatment, as findings were mixed across studies exploring this question (e.g., five additional years versus two). A key limitation across the research is that long-term effects on the skeleton and on cardiovascular function are not fully established beyond the extended follow-up of the largest studies.

Key Studies & References Meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer (Covers ORR, TTP comparisons)

Frequently Asked Questions (FAQ)

Common questions about Biostrol (FAQ)

Q: What is the main thing Biostrol is prescribed for?

Official regulatory documents indicate that Biostrol (Anastrozole) is primarily prescribed as a targeted endocrine therapy. Its use is specifically for postmenopausal women who have hormone-receptor-positive malignant disease.

Q: How is Biostrol different from other similar treatments I've seen advertised?

Biostrol is classified as a non-steroidal aromatase inhibitor, a specific pharmacological class. This means it works by highly selectively blocking the enzyme responsible for converting hormones into estrogen in peripheral tissues. This focused mechanism of action is what defines its use as a modern endocrine agent.

Q: How long does it typically take before someone feels the effect of Biostrol?

Official documents focusing on the drug's mechanism of action indicate that the initial effect of estrogen suppression occurs rapidly. This change in hormone levels typically begins within hours or days of starting treatment.

Q: If I miss a dose of Biostrol, what should I generally do?

Patient information guidelines describe a general procedure to follow if a dose is missed. This procedure involves taking the dose as soon as it is remembered, unless the time is less than 12 hours until the next scheduled dose, in which case the missed dose is typically skipped.

Q: Is Biostrol safe to use with standard painkillers like ibuprofen or acetaminophen?

Standard drug interaction databases do not indicate a major drug-to-drug interaction between Biostrol and common painkillers such as acetaminophen or ibuprofen. Reviewing the use of all medications with a healthcare professional remains standard practice.

Q: Are there any common vitamins or supplements that should not be taken with Biostrol?

Regulatory information suggests that Biostrol is generally unlikely to cause clinically significant issues by inhibiting common metabolic enzymes. Consistent with standard medical guidance, a discussion of all products, including supplements and herbal remedies, with a healthcare professional is recommended.

Q: Is there a generic version of Biostrol available?

Yes. The active ingredient in Biostrol, which is Anastrozole, is generally available as a generic medication. The availability of a generic alternative often means it can be obtained at a lower cost than the brand-name product.

Q: Is it true that Biostrol has a 'Black Box Warning'?

No. The official FDA prescribing information for Biostrol (Anastrozole) does not contain a Black Box Warning (BBW). A Black Box Warning is the highest safety alert required by the FDA for certain prescription medicines.

Q: Are there any long-term health concerns associated with Biostrol use?

Official prescribing information recognizes an increased risk of bone fracture, osteoporosis, and decreased bone mineral density as potential long-term consequences of the medication. Additionally, the long-term effects on cardiovascular function continue to be examined in clinical follow-up studies.

Q: Can Biostrol cause changes in mood or weight?

Official safety data reports that changes in mood, including depression, and weight gain are potential side effects. These effects have been reported in clinical trials involving patients taking the medication.

Q: Why do doctors prescribe Biostrol instead of something else?

Biostrol is an established option because it is a highly selective agent. Its design allows it to achieve significant estrogen suppression by targeting the aromatase enzyme without inhibiting the production of other essential adrenal hormones, such as cortisol.

Q: Does Biostrol interact with caffeine or alcohol?

Official regulatory labeling does not indicate that alcohol consumption directly causes drug interaction problems with Biostrol. However, because alcohol may potentially exacerbate existing central nervous system side effects like hot flushes or tiredness, this is a factor sometimes noted in patient information.

Q: Are there any specific lifestyle factors mentioned in the patient information for Biostrol?

Patient information often includes general recommendations for maintaining good health and fitness. These typically involve advice regarding a healthy diet and the use of gentle exercise, which may help manage certain documented side effects like fatigue and joint pain.

Q: Is Biostrol a drug that needs special monitoring?

Yes. Regulatory guidance states that monitoring of bone mineral density (BMD) and cholesterol levels should be considered for patients taking this medication. This monitoring helps manage potential long-term effects associated with the drug's mechanism of action.

Q: Can Biostrol affect other medications I take for high blood pressure?

Official clinical trial data list hypertension (high blood pressure) itself as a common adverse reaction associated with Biostrol use. This is a factor noted for healthcare professional consideration during co-administration of any other medications, including those for existing blood pressure management.

Q: If I have a history of allergies, is Biostrol still an option?

Biostrol is formally contraindicated in patients with a known hypersensitivity to the drug's active ingredient or its inactive components. Serious allergic reactions like anaphylaxis (a severe, life-threatening allergic reaction) and swelling of the face, lips, or throat have been reported.

Q: Is it necessary to take Biostrol at the exact same time every day?

Regulatory guidance states the tablet should be taken once daily. The standard patient guidance for a missed dose, which provides a window of approximately 12 hours, emphasizes the importance of consistent daily dosing rather than requiring an adherence to the exact minute.

Q: What is the shelf life of Biostrol tablets?

Official product monographs provide specific storage conditions that define the drug's stability. Biostrol is typically stored at a controlled room temperature, often specified between 15 C and 30 C, to ensure the product remains effective for its full shelf life.

Q: Can Biostrol impact fertility or reproductive health?

Biostrol is contraindicated for use in pre-menopausal women and may potentially cause fetal harm. Regulatory guidelines indicate that patients who are of reproductive potential must use effective contraception during and for a period following treatment.

Q: Is Biostrol a controlled substance?

No. Biostrol (Anastrozole) is officially classified as a non-controlled, prescription-only medication. A controlled substance designation is typically reserved for drugs with a potential for dependence or abuse.

Q: Why is Biostrol only available by prescription?

Its status as a prescription-only drug is necessary due to its classification as a potent endocrine agent. The medication requires professional oversight for proper administration and medical monitoring for potential effects on bone density and cholesterol levels.

Q: Are there special patient assistance programs for Biostrol?

Yes, patient assistance programs (PAPs) are often available. These programs, frequently offered by the manufacturers of the original brand-name drug, are designed to help eligible patients access their medication at a reduced or no cost.

Q: Is Biostrol associated with any changes in vision or hearing?

Official documents indicate that vision changes, including blurred vision, have been reported as potential side effects. Guidance stresses the importance of informing a healthcare provider immediately should a patient experience any sudden changes or worsening of vision.

How should Biostrol be stored and disposed of?

How to Store and Dispose of Biostrol?

This section details the official regulatory requirements for the storage, handling, and disposal of Biostrol, based on government-issued labeling.


Storage and Handling Requirements

Condition Requirement (Official Labeling)
Temperature Store strictly within the specified temperature range (e.g., 20 C to 25 C), and avoid storage above the maximum labeled temperature.
Protection Keep the product in its original container to protect it from moisture and direct light. Do not freeze Biostrol, as this may compromise product stability.
In-Use Stability If applicable, use the product or any reconstituted solution within the specific time frame defined in the official labeling.
Child Safety Keep Biostrol out of the sight and reach of children at all times.

Official Disposal Instructions

To dispose of unused or expired Biostrol, the preferred method is to return it to a drug take-back program or an authorized collection site. If a take-back option is not available, mix the medicine with an unappealing substance, place it in a sealed container, and discard it in the household trash, ensuring all personal information is removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biostrol found in:

A-Z Index: